Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

BACKGROUND: No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung. This study was conducted to investigate the long-term efficacy and safety of bosentan for PH bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yosuke, Hino, Mitsunori, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729252/
https://www.ncbi.nlm.nih.gov/pubmed/29237441
http://dx.doi.org/10.1186/s12890-017-0523-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729252/
https://www.ncbi.nlm.nih.gov/pubmed/29237441
http://dx.doi.org/10.1186/s12890-017-0523-2

Ejemplares similares